The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraemar Shipping Regulatory News (BMS)

Share Price Information for Braemar Shipping (BMS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 275.00
Bid: 268.00
Ask: 280.00
Change: -1.00 (-0.36%)
Spread: 12.00 (4.478%)
Open: 275.00
High: 275.00
Low: 275.00
Prev. Close: 275.00
BMS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on trading, FY23 results & investigation

26 Jun 2023 07:00

RNS Number : 8117D
Braemar PLC
26 June 2023
 

 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

 

26 June 2023

 

 

BRAEMAR PLC

("Braemar", the "Company" or the "Group")

 

Update on FY23 trading

Publication of FY23 results & investigation into a 2013 transaction

Braemar (LSE: BMS), a provider of expert investment, chartering, and risk management advice to the shipping and energy markets, provides an update on its annual results for the 12 months ended 28 February 2023 ("FY23") together with details of an on-going investigation into a historic transaction.

 

Trading Update

As announced on 22 March 2023, Braemar is pleased to reconfirm its expectation of reporting record revenue and record profitability for FY23, with revenue for the year of not less than £150m (2022: £101.3m), underlying operating profit of not less than £20m (2022: £10.1m) and net cash of £6.9m at the year end. It remains the board's intention to recommend a final dividend of 8 pence per share (2022: 7 pence) to shareholders for approval at the forthcoming annual general meeting, representing a dividend for the year of 12 pence per share, a 33% increase over the previous year (2022: 9 pence).

 

Publication of FY23 results & investigation into 2013 transaction

During the past two years, in addition to establishing and developing the Group's growth strategy, the board has focused on ensuring that proper procedures are in place to deliver good practice throughout the business as it scales. As part of this work, the board and the Group's auditors have been carrying out an investigation into a particular transaction of circa $3m, which originated in 2013, and involves payments being made through to 2017.

 

The board is not presently comfortable with the manner in which the transaction has been historically represented and the remaining liability recorded in the Company's balance sheet. Upon conclusion of the investigation, should this liability be released, it would not affect the underlying trading profit or cash position of the Company for FY23.

 

The investigation into this transaction and any related matters which may arise, is still ongoing. The board has appointed FRP, an independent specialist firm to assist with the investigation and has established a specific investigation committee, chaired by the Group's non-executive Chairman, to oversee the matter. As a result, the Company's Final results for FY23 will be delayed until this work has completed and will not be published by 30 June 2023.

 

Under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Company is required to publish its audited FY23 results by 30 June 2023. As the Company does not expect to be able to comply with this requirement, the Group will request that trading in the Company's ordinary shares be suspended with effect from 7.30 a.m. on 3 July 2023.

 

The Company will provide further updates on expected timings for publication of its FY23 results in due course. The Company expects to request a restoration of the listing of its ordinary shares on publication of its FY23 results.

 

 

 

ENDS

For further information, contact:

Braemar Plc

James Gundy, Group Chief Executive Officer

Tel +44 (0) 20 3142 4100

Nick Stone, Chief Financial Officer

Investec Bank plc

Gary Clarence / Harry Hargreaves / Alice King

Tel +44 (0) 20 7597 5970

Cenkos Securities plc

 

Ben Jeynes / Max Gould (Corporate Finance)

 

Alex Pollen / Leif Powis (Sales)

 

Tel +44 (0) 20 7397 8900

Buchanan

Charles Ryland / Jamie Hooper / Jack Devoy

Tel +44 (0) 20 7466 5000

 

Notes to Editors:

 

About Braemar Plc

Braemar provides expert investment, chartering, and risk management advice that enable its clients to secure sustainable returns and mitigate risk in the volatile world of shipping and energy. Our experienced brokers work in tandem with specialist professionals to form teams tailored to our customers' needs, and provide an integrated service supported by a collaborative culture.

 

Braemar joined the Official List of the London Stock Exchange in November 1997 and trades under the symbol BMS.

 

For more information, including our investor presentation, visit www.Braemar.com and follow Braemar on LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUCCQUPWGRA
Date   Source Headline
2nd Apr 20247:00 amRNSTotal Voting Rights
20th Mar 20247:00 amRNSFY24 Trading Update
29th Feb 202412:24 pmRNSHolding(s) in Company
29th Feb 202412:22 pmRNSTotal Voting Rights
31st Jan 20243:50 pmRNSTotal Voting Rights
3rd Jan 202411:21 amRNSHolding(s) in Company
2nd Jan 20241:29 pmRNSTotal Voting Rights
20th Dec 20233:53 pmRNSDirector/PDMR Shareholding
18th Dec 20231:34 pmRNSResults of Annual General Meeting
12th Dec 20234:58 pmRNSGrant of Share Incentives to PDMRs
7th Dec 20237:00 amRNSChange of Joint Corporate Broker
1st Dec 20231:18 pmRNSDividend Payment Date Update
29th Nov 20237:00 amRNSInterim Results
23rd Nov 20232:49 pmRNSNotice of AGM
21st Nov 20237:37 amRNSRestoration of Listing
21st Nov 20237:30 amRNSRestoration - Braemar Plc
20th Nov 20239:17 amRNSAnnual Report in European Single Electronic Format
16th Nov 20237:00 amRNSFY23 Final Results
14th Nov 20237:00 amRNSNotice of Results and Dividend Update
31st Oct 202312:29 pmRNSTotal Voting Rights
26th Oct 20237:00 amRNSTrading and FY23 Results Publication Update
22nd Sep 20237:00 amRNSUpdate on Trading, FY23 Results and Investigation
31st Aug 20237:00 amRNSTotal Voting Rights
10th Aug 202312:59 pmRNSBlock listing Interim Review
9th Aug 202310:56 amRNSResults of Annual General Meeting
1st Aug 20231:47 pmRNSAppointment of Group Chief Financial Officer
31st Jul 20231:32 pmRNSTotal Voting Rights
17th Jul 20233:41 pmRNSAGM Statement
5th Jul 20235:40 pmRNSHolding(s) in Company
3rd Jul 20239:33 amRNSTemporary Suspension
3rd Jul 20237:30 amRNSSuspension - Braemar Plc
30th Jun 20237:00 amRNSTotal Voting Rights
26th Jun 20237:00 amRNSUpdate on trading, FY23 results & investigation
20th Jun 20237:00 amRNSDirectorate Change
2nd Jun 202310:44 amRNSCapital Reduction – Court approval
31st May 202311:56 amRNSTotal Voting Rights
23rd May 20234:31 pmRNSUpdate on publishing accounts
17th May 20237:00 amRNSAnnouncement of Board Appointment
16th May 202311:07 amRNSHolding(s) in Company
28th Apr 20237:00 amRNSTotal Voting Rights
18th Apr 202312:05 pmRNSResults of General Meeting
31st Mar 20238:33 amRNSTotal Voting Rights
29th Mar 202311:40 amRNSPublication of Circular & General Meeting Notice
22nd Mar 20237:00 amRNSTrading update - a record year for Braemar
28th Feb 20232:54 pmRNSTotal Voting Rights
27th Feb 20239:20 amRNSDirector/PDMR Shareholding
16th Feb 20234:16 pmRNSGrant of Share Incentives to PDMRs
14th Feb 20237:00 amRNSTrading Update and Proposed Capital Reduction
10th Feb 20231:50 pmRNSBlock listing Interim Review
1st Feb 20232:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.